ReviewHuman vaccines & immunotherapeutics2020
Recent advances in vaccine and immunotherapy for COVID-19.
Review in Human vaccines & immunotherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Countering the threatening surge in SARS-CoV-2 variants in China and its possible global implications: stocktaking in the ongoing FISU and the Asian Games vigilance.Annals of medicine and surgery (2012) · 2024Article
- Newer emerging SARS-COV2 variant: Omicron EG.5.Annals of medicine and surgery (2012) · 2023Article
- COVID-19 vaccines and their underbelly: Are we going the right way?Health science reports · 2023Article
- Unravelling COVID-19 vaccination attributes worldwide: an extensive review regarding uptake, hesitancy, and future implication.Annals of medicine and surgery (2012) · 2023Article
- End of the COVID-19 pandemic: Is it a reality?International journal of surgery open · 2023Article
- Omicron (B.1.1.529) variant and its subvariants and lineages may lead to another COVID-19 wave in the world? -An overview of current evidence and counteracting strategies.International journal of surgery open · 2023Article
- Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review.Frontiers in immunology · 2023Review
- Enhancing COVID-19 tracking apps with human activity recognition using a deep convolutional neural network and HAR-images.Neural computing & applications · 2023Article
- Comprehensive Highlights of the Universal Efforts towards the Development of COVID-19 Vaccine.Vaccines · 2022Review
- Outer Membrane Vesicles: An Emerging Vaccine Platform.Vaccines · 2022Review
- 3D Bioprinted Neural-Like Tissue as a Platform to Study Neurotropism of Mouse-Adapted SARS-CoV-2.Advanced biology · 2022Article
- An insight to the therapeutic potential of algae-derived sulfated polysaccharides and polyunsaturated fatty acids: Focusing on the COVID-19.International journal of biological macromolecules · 2022Review
- Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities.Medical review (2021) · 2022Review
- COVID-19 vaccine candidates and vaccine development platforms available worldwide.Journal of pharmaceutical analysis · 2021Article
- Inferring a cause-effect relationship between lockdown restrictions and COVID-19 pandemic trend during the first wave.Health policy (Amsterdam, Netherlands) · 2021Article
- The COVID-19 pandemic face mask waste: A blooming threat to the marine environment.Chemosphere · 2021Review
- Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform.Vaccines · 2021Review
- Higher albumin levels on admission predict better prognosis in patients with confirmed COVID-19.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic caused by SARS-CoV-2 has resulted in millions of cases and hundreds of thousands of deaths. Beyond there being no available antiviral therapy, stimulating protective immunity by vaccines is the best option for managing future infections. Development of a vaccine for a novel virus is a challenging effort that may take several years to accomplish. This mini-review summarizes the immunopathological responses to SARS-CoV-2 infection and discusses advances in the development of vaccines and immunotherapeutics for COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.